

# Zydelig - (100 mg and 150 mg; Tablets)

| Generic Name          | Idelalisib   | Innovator            | Gilead              |
|-----------------------|--|----------------------|---------------------|
| Dosage                | 100 mg and 150 mg ; Tablets  | Branded US Sales     | Less Than \$1000 mn |
| Probable FTF          | Less Than 5  | Known Para IV Filers | Less Than 5         |
| Other ANDA developers | Less Than 5  | Tentative Approvals  | None                |
| Final Approvals       | None   | Generic Launches     | None                |
| Indication            | Zydelig is a kinase inhibitor indicated for the treatment of patients with: • Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. • Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies. • Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies. |                      |                     |
| Complexities          | Yes  |                      |                     |

### **Chronology Of Events**

Please Contact contact@researchdelta.com to get Detailed Information.

## **Executive Summary**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

#### **Patent Status**

Please Contact contact@researchdelta.com to get Detailed Information.

### **Launch Timelines and Competition**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

### **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.